text_1: Daraprim is still underpriced, relative to its peers.
text_2: "Shkreli, the CEO of Turing Pharmaceuticals, said, ""Daraprim is still underpriced, relative to its peers."" By his own estimates, Daraprim is cheaper than cancer and rare disease drugs, which he considers Daraprim’s ""peers."" By others, Daraprim costs about the same, if not more. Yet experts told us cancer and rare disease drugs are not Daraprim’s peers. Daraprim’s patent expired more than six decades ago and is a niche generic drug. The same cannot be said of cancer treatments."